

History/Clinical Dx: Endometrial cancer, pelvic organ prolapse

Postoperative Dx: Same, pending pathology examination

### Specimen(s) Received:

A: Uterus, cervix, tubes and ovaries

B: Left pelvic lymph nodes

C: Left aortic lymph nodes

D: Right pelvic lymph nodes E: Right caval lymph nodes

# **DIAGNOSIS:**

Gender:

Physician(s); cc:

Uterus, cervix tubes and ovaries:

WELL-DIFFERENTIATED ENDOMETRIAL ADENOCARCINOMA, ENDOMETRIOID TYPE WITH MUCINOUS DIFFERENTIATION (FIGO grade 1)

Type of specimen:

Hysterectomy and bilateral salpingoopherectomy

Tumor location: Tumor size:

Endometrium 3.5 cm

Histologic type:

Endometriold type with mucinous differentiation

Histologic grade:

Well differentiated (FIGO grade 1)

Depth of myometrial invasion: Less than 1 mm out of a 2.5 cm myometrial thickness

Pt Phone no

Cervical involvement: Not involved

Vaginal involvement: Vaginal cuff not involved

Adnexal involvement: Not involved Parametrial involement: Not involved

Invasion of contiguous structures: Not involved Lymphovascular invasion: None identified Perineural invasion: None identified

Resection margins:

Free of carcinoma

Lymph node involvement:

35 lymph nodes free of metastatic tumor (see parts B through E)

Reported:

Peritoneal cytology:


Other findings:

Negative for malignancy

1. Cervix with moderate to severe squamous dysplasia (CIN II-III); vaginal cuff margin free of dysplasia

2. Cervical and vaginal hyperkeratosis

3. Myometrial adenomyosis and leiomyoma



Septiment Statement:
The hability statement may be applicate to some of the compressed which independing the above report. This rest was devokant and as particularly characteristics determine and maked or appropriate the U.S. Foot and Drug development. The FOA has determined that was character a appropriate and notices say. The test in most be observed unless one or an appropriate and notices say. The test is most be observed unless one of a summand of the U.S. Foot and the observed of the





- B. Left pelvic lymph nodes:
  - 15 lymph nodes free of metastatic tumor
- C. Left aortic lymph nodes

Benign fibroadipose and muscular tissue; no lymphoid tissue identified

D. Right pelvic lymph nodes:

18 lymph nodes free of metastatic tumor

E. Right caval lymph nodes:

2 lymph nodes free of metastatic tumor

### Comments:

has reviewed this case and concurs.

# **Gross Description**

A. Received in formalin labeled uterus, cervix, bilateral tubes and ovaries" is a previously opened uterus and cervix with attached right and left fallopian tubes and ovaries, 336.0 grams. The uterus is symmetrical in configuration, 11.0 cm in length, 7.5 cm in broadest extent, and up to 5.5 cm anterior-posteriorly. The serosa is pink-tan, smooth and glistening. The cervix with attached vaginal cuff is 4.0 x 4.0 x 4.0 cm, and appears grossly normal. A portion of the cervix has been removed intraoperatively and submitted for cancer research. Cross sectioning reveals a thin pink, slightly hemorrhagic endometrium, 0.1 cm in greatest thickness. A portion of the endometrium has been removed intraoperatively and submitted for cancer research. Situated along the posterior aspect of the endometrial canal is a friable, red-tan polypoid lesion, 3.5 x 3.5 cm across. The cut surface of the tumor reveals it to be grossly confined to the endometrium. At this level, the myometrium is at least 2.5 cm in thickness. There is an area of circumscribed nodularity in the uterine wall, grossly consistent with a lelomyoma of 1.0 cm. The right and left fallopian tubes are unremarkable. The right and left ovaries are each approximately 2.0 x 1.5 x 1.0 cm, and appear grossly normal. A portion of each ovary has been removed intraoperatively and submitted for cancer research. Representative sections, blocks A1-A13.

#### **KEY TO CASSETTES:**

A1-A2 - Cervix

A3 - Upper cervical canal

A4-A8 - Tumor

A9 - Right adnexa

A10 - Left adnexa

A11 - Right parametrium

A12 - Left parametrium

A13 - Fibroid

A14-A15- Additional cervical sections

A16 - Vaginal cuff margin

B. Received in formalin labeled left pelvic lymph node" is a fragment of yellow-tan fatty soft tissue, 18.0 grams, 5.0 x 4.0 x 3.0 cm. By palpation and cross sectioning, there are multiple pink-tan rubbery lymphoid nodules, 1.5 cm in greatest dimension. The specimen in toto, blocks B1-B6.

## **KEY TO CASSETTES:**

B1 - Two lymph nodes B2 - Two lymph nodes B3 - Two lymph nodes

B4-B6 - Remainder of sample

- C. Received in formalin labeled test across sectioning, no lymph nodes are grossly identified. The specimen in toto, block C.
- D. Received in formalin labeled right pelvic lymph node" is a fragment of yellow-tan fatty soft tissue, 16.0 grams, 4.5 x 3.5 x 2.5 cm. By palpation and cross sectioning, there are multiple pink-tan rubbery lymphoid nodules, 2.0 cm in greatest dimension. The specimen in toto, blocks D1-D4.





# **Surgical Pathology Report**



**KEY TO CASSETTES:** 

D1 - Two lymph nodes
D2 - Three lymph nodes
D3-D4 - Remainder of sample

E. Received in formalin labeled (particle), right caval lymph node" is a fragment of yellow-tan fatty soft tissue, 3.0 grams, 2.0 x 1.5 x 1.0 cm. By palpation and cross sectioning, there are multiple pink-tan rubbery lymphoid nodules, 1.0 cm in greatest dimension. The specimen in toto, blocks E1-E2.

#### **KEY TO CASSETTES:**


E1 - Two lymph nodes E2 - Remainder of sample


# **Microscopic Description**

A<sub>7</sub>E. The microscopic findings support the above diagnoses.

\*\*\*Electronically Signed Out By








# **Addendum**

Patient Name: Med. Rec. #: DOB: Gender: Physician(s):





Accession #: Taken: Received: Reported:

Specimen(s) Received:
A: Uterus, cervix, tubes and ovaries

B: Left pelvic lymph nodes

C: Left aortic lymph nodes D: Right pelvic lymph nodes E: Right caval lymph nodes

# **Date Ordered:**

Status: Signed Out

<u>Addendum Comment</u>
The mucinous differentiation involves less than 10% of the endometrial tumor.

\*\*\*Electronically Signed Out\*\*\*

Regulatory Statement:
The following sinkerned may be applicable to some of the rebeen cleared or approval by the U.S. Food and Drug Admenresearch: "This laboratory is cerelled under the Clinical Labo-

